From Diabetes Tool to GLP-1 Sidekick
CGM wearables for weight loss are continuous glucose monitoring devices paired with software that help users track blood sugar in real time and translate those readings into practical food, activity, and lifestyle decisions that improve metabolic health and long-term weight management outcomes, especially when combined with GLP-1 medications. Originally designed for people with diabetes, CGMs are now being reframed as GLP-1 continuous glucose monitors that support a broader metabolic health mission. As weight-loss injections like Ozempic and Wegovy suppress appetite, they leave a gap: users still need to learn how different meals affect their glucose and energy. Metabolic health wearables step into that gap, turning raw glucose curves into patterns that show which foods keep levels steady and which trigger spikes. The result is a feedback loop that helps GLP-1 users build sustainable habits instead of relying on medication alone.
Signos Raises $20M to Build AI Coaching Around CGMs
Signos is emblematic of this shift, securing USD 20 million (approx. RM92.0 million) to expand its CGM and behavioral coaching platform for weight management in the GLP-1 era. The company offers an FDA-cleared, over-the-counter wearable that continuously monitors glucose and feeds data into an AI layer that provides metabolic guidance, gamified tools, and "Weight Loss Signal" analytics. Backers include Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama via 450 Ventures, highlighting cross-industry belief that CGMs can address GLP-1 maintenance problems rather than short-term weight loss alone. Signos reports it has grown 10-fold over the past six months as more users seek data-driven options alongside medications. According to Signos CEO Sharam Fouladgar-Mercer, “the approaches that will endure are the ones that combine the best of medication with the best of personalized data.”
Behavioral Coaching Turns Glucose Data into Daily Decisions
Raw glucose numbers mean little without context, which is why glucose monitor behavioral coaching has become the centerpiece of new metabolic health wearables. Signos’ system shows users which foods spike their glucose and which meals keep them in range, then suggests small adjustments they can test the very next day. This mirrors how sleep and recovery wearables guide behavior, but with a sharper focus on food timing, portion size, and meal composition. For GLP-1 users, the timing matters: medications dampen hunger but do not teach what or how to eat when prescriptions stop. By pairing in-app coaching with continuous data, CGM wearables for weight loss aim to build what Signos calls “metabolic self-knowledge,” helping people see cause-and-effect between choices and blood sugar in near real time, so weight loss becomes a repeatable skill instead of a one-time drug effect.
From Direct-to-Consumer Gadget to Health System Partner
The business model for CGM wearables is shifting from pure direct-to-consumer sales toward partnerships with health plans, pharma companies, and employers that are wrestling with GLP-1 costs and long-term outcomes. Signos, which started as a consumer-focused platform, is now explicitly courting health plan and pharma relationships as demand for structured GLP-1 support grows. Investor participation from Blue Cross Blue Shield of Alabama signals that insurers see CGMs as potential tools to improve maintenance and reduce rebound weight gain after GLP-1 therapy. At the same time, Dexcom is listing the Signos CGM on its consumer site Stelo.com, blending established sensor hardware with newer coaching platforms. The emerging pitch is not that CGMs replace GLP-1 drugs, but that they provide the behavioral and data backbone needed to make expensive treatments more sustainable and clinically meaningful over time.
A Complementary Future for GLP-1 and Metabolic Health Wearables
Across the wearables market, continuous glucose monitoring is being positioned as a complement, not a competitor, to GLP-1 therapy. One in eight adults has taken a GLP-1, and maintenance remains an unsolved challenge for many users once appetite suppression fades. By embedding CGMs into weight-management programs, employers, insurers, and pharma partners can frame GLP-1s as part of a broader metabolic health journey that also includes education, activity, and nutrition. Major backers like Google Ventures and Dexcom are betting that metabolic health wearables will move from niche gadgets to standard tools in weight-care pathways, similar to how heart-rate trackers became routine in fitness. GLP-1 continuous glucose monitors and AI coaching platforms promise a more continuous model of care: medication to open the door to weight loss, and real-time biosensing to help users stay there.